Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Akero Therapeutics Inc AKRO

Healthcare Biotechnology
Akero Therapeutics, Inc. is a clinical-stage company. The Company is developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, including metabolic dysfunction-associated steatohepatitis (MASH), a disease without any approved therapies. Efruxifermin (EFX), is its lead product candidate for MASH, which is being evaluated in the ongoing... see more

Recent & Breaking News (NDAQ:AKRO)

Akero Therapeutics to Present at Upcoming Healthcare Conferences in May

GlobeNewswire May 2, 2022

Akero Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results

GlobeNewswire February 25, 2022

Akero Therapeutics Completes Enrollment of Phase 2b HARMONY Study in Pre-Cirrhotic NASH Patients

GlobeNewswire February 8, 2022

Akero Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference

GlobeNewswire January 4, 2022

Akero Therapeutics to Present at the Evercore ISI 4th Annual HealthCONx Virtual Conference

GlobeNewswire November 26, 2021

Akero Presents New Analysis of Phase 2a BALANCED Study Data Showing Additional Qualitative Evidence of Histological Improvement in EFX-treated NASH Patients after 16 Weeks of Treatment

GlobeNewswire November 12, 2021

Akero Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Update

GlobeNewswire November 12, 2021

Akero Therapeutics to Present at the Jefferies London Healthcare Conference

GlobeNewswire November 9, 2021

Akero Therapeutics Receives FDA Fast Track Designation for Efruxifermin (EFX) for the Treatment of NASH

GlobeNewswire October 19, 2021

Akero Therapeutics to Present at the H.C. Wainwright 5th Annual NASH Investor Conference

GlobeNewswire October 5, 2021

Akero Therapeutics to Present at the Morgan Stanley Virtual Global Healthcare Conference

GlobeNewswire September 7, 2021

Akero Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Update

GlobeNewswire August 13, 2021

Fate Therapeutics Appoints Yuan Xu to its Board of Directors

GlobeNewswire August 4, 2021

Akero Therapeutics Appoints Judy Chou, Ph.D., to its Board of Directors

GlobeNewswire July 14, 2021

Study Published in Nature Medicine Shows Investigational NASH Drug Reduced Liver Fat to Normal Levels and Reversed Fibrosis After 16 Weeks of Treatment

GlobeNewswire July 8, 2021

Akero Therapeutics Presents at the American Diabetes Association's 81st Scientific Sessions, Demonstrating that Improvements in Adipose Tissue Metabolism Contributed Substantially to Improved Liver Health and Better Glycemic Control in Efruxifermin (EFX)-treated Pre-Cirrhotic NASH Patients

GlobeNewswire June 25, 2021

Akero Therapeutics Presents Analyses at the 2021 International Liver Congress Showing Normalization of Liver Fat Substantially Reduced Markers of Liver Injury and Fibrosis, and Greatly Increased Probability of Resolving NASH

GlobeNewswire June 21, 2021

Akero Therapeutics to Present Efruxifermin (EFX) Results Showing Histologic Improvement in EFX-Treated F4 Cirrhotic Patients as a Late-Breaker Oral Presentation at the 2021 International Liver Congress

GlobeNewswire June 1, 2021

Akero Therapeutics to Present at the Jefferies Virtual Healthcare Conference

GlobeNewswire May 28, 2021

Akero Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Update

GlobeNewswire May 13, 2021